-- Max Resource (MAX.V) 周四宣布，已申请在美国OTCQB市场上市。 该公司表示，其股票将继续在多伦多证券交易所创业板（TSX Venture Exchange）以现有股票代码进行交易。 该公司的OTCQB上市申请尚需OTC Markets的审核和批准。 该公司补充道，其股票符合通过存托信托公司（DTC）进行结算的条件，DTC负责美国上市公司的电子清算和结算。 首席执行官Brett Matich表示：“我们相信，在OTCQB上市将扩大Max在美国投资者中的影响力，提高交易的便捷性和流动性，并有助于公司在勘探季全面展开之际，拓展更广泛的国际股东基础。” 截至发稿时，该公司股票在TSX Venture Exchange的股价下跌0.025美元，至0.28美元。
Price: $0.28, Change: $-0.03, Percent Change: -8.20%
HawkEye 360 (HAWK) shares rose nearly 30% in their New York Stock Exchange debut Thursday.The stock opened at $33.80 per share, higher than the initial public offering price of $26 per share.The company priced its IPO of 16 million shares for gross proceeds of about $416 million. The offering is expected to close Friday.Price: $33.77, Change: $+7.77, Percent Change: +29.88%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target by $33 to $317, 24x our 2026 EPS estimate and in line with the shares' ten-year average forward multiple. We lower our 2026 EPS view to $13.21 from $13.44 and 2027's to $14.11 from $14.27. We upgrade MCD from Hold to Buy. Shares trade at a 12% discount to their ten-year forward average, creating an attractive entry point despite near-term margin headwinds from restaurant operating costs, particularly beef costs. We expect margin normalization as traffic gains scale and value messaging matures. Q1 results outperformed on total revenue, global comps, and adjusted EPS, with developed market comps of +3.9%, improving 490 bps sequentially, and developing markets maintaining momentum at +3.4%. In our view, results suggest value positioning is resonating globally and driving traffic recovery. MCD's category expansion into chicken and beverages provides incremental growth optionality, while >80% free cash flow conversion supports continued investment in restaurant development and shareholder returns.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target price at $19, which is 16.5x our 2027 EPS view of $1.15, a discount to the trading multiple of 18.1x since going public in 2023. We think this multiple is justified given the litigation overhang and limited visibility into KVUE's standalone performance (the company is no longer providing forward-looking guidance and hosting an analyst call) due to the pending acquisition by Kimberly-Clark (KMB), expected to close during 2H 2026. We increase our 2026 EPS estimate to $1.15 from $1.10 following this morning's Q1 earnings release. We maintain our 2027 EPS estimate at $1.15. Kenvue delivered a solid first quarter that demonstrated continued operational momentum. Net sales increased to $3,909M (+4.5% Y/Y) with organic growth of 0.7%. The performance suggests management's operational initiatives are gaining traction as the company approaches the transaction close. The transaction received shareholder approval in January 2026, and regulatory approvals are progressing.